Something changed three weeks ago. Here is what happened plus some context, and hopefully clear up any confusion on the "there's no evidence" nonsense
The short version. On 23 and 24 July 2026, an FDA advisory committee voted in favour of allowing several widely used peptides, including BPC-157, KPV, TB-500 and MOTS-c, onto the list of substances that compounding pharmacies in the US are permitted to work with.
FDA's Pharmacy Compounding Advisory Committee met over two days to consider seven peptides. They were answering one question: should these be added to the 503A list, which is the list of ingredients a compounding pharmacy is allowed to make up on a prescription.
Six of the seven got a favourable vote. One did not.
| Peptide | Committee vote |
|---|---|
| BPC-157 | 8 to 6 in favour, 1 abstention |
| KPV | 8 to 6 in favour, 1 abstention |
| TB-500 | 8 to 6 in favour, 1 abstention |
| MOTS-c | 7 to 5 in favour, 2 abstentions |
| Epitalon | 7 to 5 in favour, 1 abstention |
| Semax | 8 to 5 in favour |
| Emideltide | 6 to 7 against. Rejected. |
FDA's own scientific reviewers had recommended against all seven of these peptides ahead of the meeting. Their reasons: not enough trial data in people, not enough known about exactly what is in the material being sold, and the risk of an immune reaction when injected peptides are not made to a tight enough standard, which is legitimate if untested peptides are being injected.
The committee went against its own agency's staff on six of the seven. Note what the FDA objection actually was, because it gets repeated carelessly: not that these compounds are unstudied, but that the studies are the wrong shape, meaning few large controlled trials in humans. That distinction matters, and the next section deals with it properly.
We must factor in that there are different agendas within the organisation and the institutions that fund them.
Read this bit before repeating any of it.
This is the part most people get wrong, in both directions. It is not because the compounds were tested and failed. It is mostly economics.
Taking any compound from first-in-human through to approval costs somewhere in the region of 1.3 to 2.6 billion dollars over ten to fifteen years. No company spends that without the exclusive right to sell it at the end. And a compound that sits very close to something the body already makes is hard to protect: you cannot patent a naturally occurring molecule as such, only specific analogues, formulations, methods of use or manufacturing processes.
Semaglutide, the molecule in Ozempic and Wegovy, is an engineered analogue of a human hormone. It was deliberately modified so it survives longer in the body, and those modifications are patentable. That patent is what justified the spend on the trials, and the trials are what produced the approval.
Mounjaro works on the same principle but is not strictly a GLP-1: tirzepatide activates two receptors, GIP and GLP-1. There are also several other approved drugs in this family beyond the two everyone names, including liraglutide, dulaglutide and exenatide.
One useful complication: exenatide originally derives from Gila monster venom, a naturally occurring peptide. It was patented and approved anyway. The line between natural and engineered is a real factor in this story, but it is a tendency, not a law.
It would be convenient to say every peptide without approval is a victim of patent economics. That is not true, and it is worth being straight about.
Retatrutide is the clearest example. It is an engineered Eli Lilly molecule that activates three receptors, it is firmly patented, and it has now produced several successful Phase 3 trials. It is unapproved today because it is still going through the process, not because nobody could own it. It is on track, not shut out.
So there are two different situations sitting under the same word. One is a compound nobody will fund because there is no money in owning it. The other is a compound working its way through a full trial programme that has not finished yet. Both are unapproved. They are not the same thing, and anyone telling you otherwise is simplifying to make a point.
Usually said by people who have not looked. PubMed returns hundreds of published papers on BPC-157 alone, going back to the early 1990s. The research exists, and it has done for decades.
What is true is that there have been very few big human trials. But look at why. Nobody funds a trial costing a billion dollars without the exclusive rights waiting at the end. The missing trials are about the money, not a verdict on the compound.
| The claim | Accurate? |
|---|---|
| "There are no large industry-funded human trials" | True. That is the real gap. |
| "There is no evidence" | False. Hundreds of published papers say otherwise. |
Both the hype and the dismissal depend on blurring those two.
Thymosin beta-4, the parent molecule of TB-500, has been through published human trials at the exact standard regulators ask for. Randomised, placebo-controlled and double-masked. Phase 2 trials in severe dry eye hit their endpoints, with significant improvement in both symptoms and corneal staining against placebo. There is a published Phase 3 in neurotrophic keratopathy. That is peer-reviewed human evidence, sitting on PubMed, right now.
BPC-157 has been into human trials too, including a multicentre randomised double-blind placebo-controlled Phase 2 in ulcerative colitis. It did not fail. The full results were simply never published as a standalone paper and the programme was never carried forward, which is what happens when the money runs out rather than when the science does.
So the honest gap is not "no human evidence". It is that nobody has paid for the large, repeated, fully published programme a regulator needs before it will sign a label. That is a funding problem, not a science problem, and it is the same funding problem described above.
The regulatory position on several widely used peptides moved meaningfully in July, and it moved in one direction. That is worth saying plainly. It is also worth saying that we expect more friction from here, not less.
There are a lot of layers to this, and the one most people skip is the money. Pain management is roughly an 80 billion dollar a year drug market globally. A compound that reduced how much of that market was needed would not arrive as a new product for the companies already in it. It would arrive as a subtraction from the one they have.
That does not need anybody to act in bad faith, which is exactly why it is worth understanding. The reason to protect and grow a product line already earning billions is enormous. The reason to fund something that would eat into it, and that you could not own exclusively anyway, is zero. Put those side by side and you do not need a conspiracy to explain why a compound first described more than thirty years ago is only now reaching a committee vote.
Big money and big players are involved. They will still be involved in 2027.
Our position has not changed with the vote. We work only with material that has been tested, batch by batch, and we would rather tell you a batch failed than tell you a committee voted.
Accurate as of 10 August 2026. This area has moved twice in the last five months, so treat anything older than that with suspicion, including this page. Information only, not medical advice. Anything you take should be decided with us, on a protocol, not off a web page.